Comments on: Riliprubart by Sanofi for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval /data-insights/riliprubart-sanofi-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ The leading site for news and procurement in the pharmaceutical industry Tue, 21 Jan 2025 01:08:23 +0000 hourly 1 https://wordpress.org/?v=6.7.2